USP Rivalry With US FDA Over Compendial Standards Provision Busts Into Open Legislative Fight
Executive Summary
In a letter to Senate HELP Committee chairman Sen. Lamar Alexander and ranking member Sen. Patty Murray, USP and other stakeholders are calling for the removal of language that would exclude biological products from requirements to follow USP quality standards.
You may also be interested in...
Biosimilars In US Drug Pricing Debate: Second Chance – Or Maybe Last Chance
Current drug pricing legislative effort offers the prospect of a substantial update to 2010 biosimilar law – substantial at least in the list of statutory changes, if not in the potential near term impact on the marketplace.
US FDA, USP Cooperate On Small Molecule Drug Monograph Updates To Speed ANDAs
Generic applicants can request monograph changes while FDA assessment is ongoing.
USP Standards For Biological Drugs Would Restrict Innovation, US FDA Says
Top officials at the US FDA explain why the agency opposes USP monographs for biological products as a Senate committee proposes to disallow them and the USP launches an advertising campaign in their favor.